GR 125487

Drug Profile

GR 125487

Latest Information Update: 08 Dec 2000

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Indoles; Small molecules; Sulfonamides
  • Mechanism of Action Serotonin 4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Irritable bowel syndrome

Most Recent Events

  • 08 Dec 2000 Profile reviewed but no significant changes made
  • 09 May 1996 Two studies have been added to the pharmacodynamics section ,.
  • 07 Nov 1994 No-Development-Reported for Irritable bowel syndrome in United Kingdom (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top